Dexatrim Natural Fattens Chattem's First Quarter; Extensions Planned
This article was originally published in The Tan Sheet
Executive Summary
Sales of Chattem's Dexatrim line increased nearly 5% in the fiscal first quarter ended Feb. 28 compared to the year-ago period, despite the loss of the flagship phenylpropanolamine-containing products.
You may also be interested in...
Acutrim
Health & Nutrition Systems International expects to book revenue by the end of March from its January acquisition of three Acutrim trademarks and outstanding inventory of two natural "ephedrine-free" appetite suppressant formulations for $180,000 from Heritage Brands/Insight Pharmaceuticals. West Palm Beach, Fla.-based HNS, which markets weight management and body building products such as Carb Cutter, Thin Tab and Carbolizer in gyms, health food stores and drug chains, purchased only the inventory for Acutrim Natural A.M. and P.M., which launched last June (1"The Tan Sheet" May 15, 2000, p. 7). Heritage pulled original Acutrim formulas from the market after FDA's November request that companies voluntarily halt marketing PPA-containing products. The Acutrim franchise has lost market share in recent years to ephedrine alkaloid-containing supplements
Chattem Icy Hot Patch Launch Expected To Drive Topical Analgesic Growth
Chattem is projecting $3 mil. to $5 mil. in sales growth for its topical analgesics franchise in FY 2001, primarily driven by the launch of Icy Hot Patch, the firm told analysts during an earnings conference call Jan. 26.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC